Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes - PubMed (original) (raw)
. 1999 Nov;27(11):1334-40.
Affiliations
- PMID: 10534319
Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
L C Wienkers et al. Drug Metab Dispos. 1999 Nov.
Abstract
In vitro studies were conducted to identify the hepatic cytochrome P-450 (CYP) enzymes responsible for the oxidative metabolism of the individual enantiomers of reboxetine. In human liver microsomes, each reboxetine enantiomer was metabolized to one primary metabolite, O-desethylreboxetine, and three minor metabolites, two arising via oxidation of the ethoxy aromatic ring and a third yet unidentified metabolite. Over a concentration range of 2 to 200 microM, the rate O-desethylreboxetine formation for either enantiomer conformed to monophasic Michaelis-Menten kinetics. Evidence for a principal role of CYP3A in the formation of O-desethylreboxetine for (S, S)-reboxetine and (R,R)-reboxetine was based on the results from the following studies: 1) inhibition of CYP3A activity by ketoconazole markedly decreased the formation of O-desethylreboxetine, whereas inhibitors selective for other CYP enzymes did not inhibit reboxetine metabolism, 2) formation of O-desethylreboxetine correlated (r(2) = 0.99; p <.001) with CYP3A-selective testosterone 6-beta-hydroxylase activity across a population of human livers (n = 14). Consistent with inhibition and correlation data, O-desethylreboxetine formation was only detectable in incubations using microsomes prepared from a Baculovirus-insect cell line expressing CYP3A4. Furthermore, the apparent K(M) for the O-desethylation of reboxetine in cDNA CYP3A4 microsomes was similar to the affinity constants determined in human liver microsomes. In addition, (S,S)-reboxetine and (R,R)-reboxetine were found to be competitive inhibitors of CYP2D6 and CYP3A4 (K(i) = 2.5 and 11 microM, respectively). Based on the results of the study, it is concluded that the metabolism of both reboxetine enantiomers in humans is principally mediated via CYP3A.
Similar articles
- Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A. Niwa T, et al. Drug Metab Dispos. 2000 Sep;28(9):1128-34. Drug Metab Dispos. 2000. PMID: 10950860 - Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes.
Wynalda MA, Hauer MJ, Wienkers LC. Wynalda MA, et al. Drug Metab Dispos. 2000 Sep;28(9):1014-7. Drug Metab Dispos. 2000. PMID: 10950842 - Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Jones DR, et al. J Pharmacol Exp Ther. 1999 Sep;290(3):1116-25. J Pharmacol Exp Ther. 1999. PMID: 10454485 - Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.
Fleishaker JC. Fleishaker JC. Clin Pharmacokinet. 2000 Dec;39(6):413-27. doi: 10.2165/00003088-200039060-00003. Clin Pharmacokinet. 2000. PMID: 11192474 Review. - Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.
Dostert P, Benedetti MS, Poggesi I. Dostert P, et al. Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S23-35; discussion S71-3. doi: 10.1016/s0924-977x(97)00417-3. Eur Neuropsychopharmacol. 1997. PMID: 9169308 Review.
Cited by
- Chirality of antidepressive drugs: an overview of stereoselectivity.
Vashistha VK, Sethi S, Tyagi I, Das DK. Vashistha VK, et al. Asian Biomed (Res Rev News). 2022 Apr 29;16(2):55-69. doi: 10.2478/abm-2022-0008. eCollection 2022 Apr. Asian Biomed (Res Rev News). 2022. PMID: 37551287 Free PMC article. Review. - Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Badri PS, et al. Clin Pharmacokinet. 2016 Mar;55(3):275-95. doi: 10.1007/s40262-015-0317-8. Clin Pharmacokinet. 2016. PMID: 26330025 Free PMC article. Review. - Clinically significant drug interactions with newer antidepressants.
Spina E, Trifirò G, Caraci F. Spina E, et al. CNS Drugs. 2012 Jan 1;26(1):39-67. doi: 10.2165/11594710-000000000-00000. CNS Drugs. 2012. PMID: 22171584 Review. - Getting the balance right: Established and emerging therapies for major depressive disorders.
Perović B, Jovanović M, Miljković B, Vezmar S. Perović B, et al. Neuropsychiatr Dis Treat. 2010 Sep 7;6:343-64. doi: 10.2147/ndt.s10485. Neuropsychiatr Dis Treat. 2010. PMID: 20856599 Free PMC article. - Investigation of the metabolites of (S,S)-[(11)C]MeNER in humans, monkeys and rats.
Schou M, Zoghbi SS, Shetty HU, Shchukin E, Liow JS, Hong J, Andrée BA, Gulyás B, Farde L, Innis RB, Pike VW, Halldin C. Schou M, et al. Mol Imaging Biol. 2009 Jan-Feb;11(1):23-30. doi: 10.1007/s11307-008-0175-y. Epub 2008 Sep 18. Mol Imaging Biol. 2009. PMID: 18800204 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical